STOCK TITAN
  1. Home
  2. SEC-Filings
  3. AXDX

Accelerate Diagnostics Inc SEC Filings

AXDX NASDAQ

Welcome to our dedicated page for Accelerate Diagnostics SEC filings (Ticker: AXDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Looking for FDA milestones, cash burn figures, or insider confidence at Accelerate Diagnostics? This page brings every Accelerate Diagnostics SEC filing to one place—no EDGAR maze required.

You can jump straight to an Accelerate Diagnostics annual report 10-K simplified for pipeline progress, read each Accelerate Diagnostics quarterly earnings report 10-Q filing for instrument placement trends, or scan any Accelerate Diagnostics 8-K material events explained to see when new antimicrobial panels win clearance. Our platform delivers AI-powered summaries so you understand complex microbiology jargon in plain English—perfect for understanding Accelerate Diagnostics SEC documents with AI instead of spending hours flipping pages.

Need governance detail? The Accelerate Diagnostics proxy statement executive compensation section outlines how leadership is rewarded for hitting diagnostic rollout goals. Monitoring stock moves is easy too: we surface Accelerate Diagnostics insider trading Form 4 transactions and send Accelerate Diagnostics Form 4 insider transactions real-time alerts, helping you track Accelerate Diagnostics executive stock transactions Form 4 minutes after they hit EDGAR.

Every filing—10-K, 10-Q, 8-K, S-1, or 20-F—is covered, time-stamped, and paired with concise Accelerate Diagnostics earnings report filing analysis. Our AI highlights segment revenue, R&D spend tied to the Accelerate Pheno and Arc platforms, and risk updates on antimicrobial resistance markets. Whether you’re a clinician-investor comparing quarter-over-quarter sales or an analyst verifying dilution clauses, you’ll find Accelerate Diagnostics SEC filings explained simply and updated in real time.

Filing

[Form 3] Accelerate Diagnostics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Summary

Gilbert E. Nathan has filed a Form 3 (Initial Statement of Beneficial Ownership) following his appointment as Director at Accelerate Diagnostics (AXDX). The filing, dated June 28, 2025, discloses Nathan's beneficial ownership position as of April 10, 2025.

Key details from the filing:

  • Nathan currently holds no securities (derivative or non-derivative) beneficially owned in the company
  • The filing confirms his position as Director but indicates no other roles such as Officer or 10% Owner
  • This is an individual filing, not a joint/group submission
  • Business address is listed as 3950 S. Country Club Road, Suite 470, Tucson, AZ 85714

This Form 3 filing is a standard regulatory requirement for new directors under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future ownership reporting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Accelerate Diagnostics (AXDX)?

The current stock price of Accelerate Diagnostics (AXDX) is $0.034 as of May 16, 2025.

What is the market cap of Accelerate Diagnostics (AXDX)?

The market cap of Accelerate Diagnostics (AXDX) is approximately 3.5M.

What is the core focus of Accelerate Diagnostics, Inc.?

Accelerate Diagnostics, Inc. specializes in developing rapid in vitro diagnostics to identify infectious pathogens and perform antimicrobial susceptibility testing. Their innovative systems help reduce the time clinicians wait for test results, improving patient outcomes.

How does the Accelerate ID/AST system work?

The Accelerate ID/AST system utilizes a proprietary process that combines genomic and phenotypic detection methods to rapidly identify pathogens and determine their susceptibility to antibiotics. The system’s automation streamlines sample preparation and analysis, significantly reducing turnaround times.

What technology differentiates Accelerate Diagnostics from other diagnostic companies?

Accelerate Diagnostics integrates advanced technologies such as proprietary optichem surface coatings and automated platforms like the Accelerate Pheno and Accelerate Arc systems. This integration of automation with both genomic and phenotypic testing enhances sensitivity, speed, and reliability in diagnostics.

How do Accelerate Diagnostics’ solutions impact patient care?

By providing rapid and accurate diagnostic results, the company’s systems help clinicians quickly identify infections and select the most appropriate antibiotic treatments. This swift response is especially important in managing sepsis and reducing antibiotic resistance, ultimately improving patient outcomes.

What is the significance of automated sample preparation in their systems?

Automated sample preparation minimizes human error and reduces processing time, ensuring that high-quality diagnostic information is delivered efficiently. This technology is an integral component of the company’s strategy to provide same-shift, accurate results for infectious disease management.

What market challenges does Accelerate Diagnostics address?

The company is dedicated to combating critical healthcare challenges such as antibiotic resistance and sepsis. By delivering rapid diagnostic results, their systems help shorten the time to initiate targeted antibiotic therapies, which is vital in reducing healthcare costs and improving treatment outcomes.

How does Accelerate Diagnostics generate its revenue?

Accelerate Diagnostics generates revenue primarily through the direct sale and licensing of its diagnostic systems and technologies. Their business model relies on establishing long-term partnerships with clinical laboratories and healthcare providers who value the speed and accuracy of their testing solutions.

How does the company ensure high quality and reliability in its products?

The company emphasizes rigorous validation and regulatory clearances to ensure the quality and reliability of its diagnostic systems. Continuous product development and adherence to high clinical standards enable them to meet stringent performance criteria and maintain industry trust.
Stock AXDX logo
Accelerate Diagnostics Inc

NASDAQ:AXDX

AXDX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

AXDX Stock Data

3.49M
15.63M
37.53%
18.91%
1.76%
Medical Devices
Laboratory Analytical Instruments
Link
United States
TUCSON